Disease Risk Index (DRI) Assignment Tool
About the Disease Risk Index (DRI)
The Disease Risk Index (DRI) is a validated tool to categorize groups of patients undergoing allogeneic stem cell transplantation (HCT) for hematologic malignancy by disease risk. It is intended for research purposes to stratify patients in broad disease risk categories for retrospective or prospective studies.
The DRI considers only disease-related parameters (i.e., disease, stage and, for some diseases, cytogenetics) and was developed only for the primary outcome of overall survival after HCT.
It does not consider patient-related variables such as age and co-morbidities and, therefore, is NOT intended to give an accurate prognosis for individual patients.
The DRI was developed using data in adult patients with hematologic malignancies and is not yet validated for pediatric patients.
DRI assignments
ALL - Acute lymphoblastic leukemia
Disease Stage: 2nd Complete RemissionDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- ALL - Acute lymphoblastic leukemia
- 2nd Complete Remission
- High
- 33% (31-35)
ALL - Acute lymphoblastic leukemia
Disease Stage: 3rd Complete RemissionDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- ALL - Acute lymphoblastic leukemia
- 3rd Complete Remission
- High
- 33% (31-35)
ALL - Acute lymphoblastic leukemia
Disease Stage: 1st complete remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- ALL - Acute lymphoblastic leukemia
- 1st complete remission
- Intermediate
- 51% (50-52)
ALL - Acute lymphoblastic leukemia
Disease Stage: Advanced StageDRI Assignment: Very High2-year Overall Survival*: 23% (20-27)*95% confidence intervals
- ALL - Acute lymphoblastic leukemia
- Advanced Stage
- Very High
- 23% (20-27)
AML - Acute myelogenous leukemia
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Favorable cytogenetics
- AML - Acute myelogenous leukemia
- Advanced Stage
- High
- 33% (31-35)
AML - Acute myelogenous leukemia
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Intermediate cytogenetics
- AML - Acute myelogenous leukemia
- Advanced Stage
- High
- 33% (31-35)
AML - Acute myelogenous leukemia
Disease Stage: Any Complete RemissionDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Adverse cytogenetics
- AML - Acute myelogenous leukemia
- Any Complete Remission
- High
- 33% (31-35)
AML - Acute myelogenous leukemia
Disease Stage: Any Complete RemissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Intermediate cytogenetics
- AML - Acute myelogenous leukemia
- Any Complete Remission
- Intermediate
- 51% (50-52)
AML - Acute myelogenous leukemia
Disease Stage: Any Complete RemissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- Favorable cytogenetics
- AML - Acute myelogenous leukemia
- Any Complete Remission
- Low
- 66% (63-68)
AML - Acute myelogenous leukemia
Disease Stage: Advanced StageDRI Assignment: Very High2-year Overall Survival*: 23% (20-27)*95% confidence intervals
- Adverse cytogenetics
- AML - Acute myelogenous leukemia
- Advanced Stage
- Very High
- 23% (20-27)
CLL - Chronic lymphocytic leukemia
Disease Stage: Advanced StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- CLL - Chronic lymphocytic leukemia
- Advanced Stage
- Intermediate
- 51% (50-52)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
CLL - Chronic lymphocytic leukemia
Disease Stage: Any Complete RemissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- CLL - Chronic lymphocytic leukemia
- Any Complete Remission
- Low
- 66% (63-68)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
CLL - Chronic lymphocytic leukemia
Disease Stage: Partial remissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- CLL - Chronic lymphocytic leukemia
- Partial remission
- Low
- 66% (63-68)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
CML - Chronic myelogenous leukemia
Disease Stage: Advanced StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- CML - Chronic myelogenous leukemia
- Advanced Stage
- Intermediate
- 51% (50-52)
CML - Chronic myelogenous leukemia
Disease Stage: 1st or 2nd chronic phaseDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- CML - Chronic myelogenous leukemia
- 1st or 2nd chronic phase
- Low
- 66% (63-68)
CML - Chronic myelogenous leukemia
Disease Stage: Blast phaseDRI Assignment: Very High2-year Overall Survival*: 23% (20-27)*95% confidence intervals
- CML - Chronic myelogenous leukemia
- Blast phase
- Very High
- 23% (20-27)
HL - Hodgkin lymphoma
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- HL - Hodgkin lymphoma
- Advanced Stage
- High
- 33% (31-35)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
HL - Hodgkin lymphoma
Disease Stage: Partial remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- HL - Hodgkin lymphoma
- Partial remission
- Intermediate
- 51% (50-52)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
HL - Hodgkin lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- HL - Hodgkin lymphoma
- Any Complete Remission
- Low
- 66% (63-68)
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
MDS - High-risk myelodysplastic syndrome
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Adverse cytogenetics
- MDS - High-risk myelodysplastic syndrome
- Advanced Stage
- High
- 33% (31-35)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - High-risk myelodysplastic syndrome
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Intermediate cytogenetics
- MDS - High-risk myelodysplastic syndrome
- Advanced Stage
- High
- 33% (31-35)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - High-risk myelodysplastic syndrome
Disease Stage: Early StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Adverse cytogenetics
- MDS - High-risk myelodysplastic syndrome
- Early Stage
- High
- 33% (31-35)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - High-risk myelodysplastic syndrome
Disease Stage: Early StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Intermediate cytogenetics
- MDS - High-risk myelodysplastic syndrome
- Early Stage
- Intermediate
- 51% (50-52)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - Low-risk myelodysplastic syndrome
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- Adverse cytogenetics
- MDS - Low-risk myelodysplastic syndrome
- Advanced Stage
- High
- 33% (31-35)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - Low-risk myelodysplastic syndrome
Disease Stage: Advanced StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Intermediate cytogenetics
- MDS - Low-risk myelodysplastic syndrome
- Advanced Stage
- Intermediate
- 51% (50-52)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - Low-risk myelodysplastic syndrome
Disease Stage: Early StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Adverse cytogenetics
- MDS - Low-risk myelodysplastic syndrome
- Early Stage
- Intermediate
- 51% (50-52)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
MDS - Low-risk myelodysplastic syndrome
Disease Stage: Early StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Intermediate cytogenetics
- MDS - Low-risk myelodysplastic syndrome
- Early Stage
- Intermediate
- 51% (50-52)
Disease Note: Low-risk MDS includes refractory anemia with or without ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; high-risk includes refractory anemia with excess blasts (RAEB-1 and RAEB-2).
Myeloproliferative neoplasm
Disease Stage: Any stageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- Myeloproliferative neoplasm
- Any stage
- Intermediate
- 51% (50-52)
NHL - Aggressive non-Hodgkins lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - Aggressive non-Hodgkins lymphoma
- Any Complete Remission
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Aggressive non-Hodgkins lymphoma
Disease Stage: Partial remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - Aggressive non-Hodgkins lymphoma
- Partial remission
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Aggressive non-Hodgkins lymphoma
Disease Stage: Advanced StageDRI Assignment: Very High2-year Overall Survival*: 23% (20-27)*95% confidence intervals
- NHL - Aggressive non-Hodgkins lymphoma
- Advanced Stage
- Very High
- 23% (20-27)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Burkitt lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- NHL - Burkitt lymphoma
- Any Complete Remission
- High
- 33% (31-35)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Burkitt lymphoma
Disease Stage: Partial remission/Advanced stageDRI Assignment: Very High2-year Overall Survival*: 23% (20-27)*95% confidence intervals
- NHL - Burkitt lymphoma
- Partial remission/Advanced stage
- Very High
- 23% (20-27)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Indolent non-Hodgkins lymphoma
Disease Stage: Advanced StageDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - Indolent non-Hodgkins lymphoma
- Advanced Stage
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Indolent non-Hodgkins lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- NHL - Indolent non-Hodgkins lymphoma
- Any Complete Remission
- Low
- 66% (63-68)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Indolent non-Hodgkins lymphoma
Disease Stage: Partial remissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- NHL - Indolent non-Hodgkins lymphoma
- Partial remission
- Low
- 66% (63-68)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Mantle cell lymphoma
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- NHL - Mantle cell lymphoma
- Advanced Stage
- High
- 33% (31-35)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Mantle cell lymphoma
Disease Stage: Partial remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - Mantle cell lymphoma
- Partial remission
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - Mantle cell lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: Low2-year Overall Survival*: 66% (63-68)*95% confidence intervals
- NHL - Mantle cell lymphoma
- Any Complete Remission
- Low
- 66% (63-68)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - T-cell non-Hodgkin’s lymphoma
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- NHL - T-cell non-Hodgkin’s lymphoma
- Advanced Stage
- High
- 33% (31-35)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - T-cell non-Hodgkin’s lymphoma
Disease Stage: Any Complete RemissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - T-cell non-Hodgkin’s lymphoma
- Any Complete Remission
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
NHL - T-cell non-Hodgkin’s lymphoma
Disease Stage: Partial remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- NHL - T-cell non-Hodgkin’s lymphoma
- Partial remission
- Intermediate
- 51% (50-52)
Disease Note: Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group. Aggressive B-NHL includes diffuse large B cell lymphoma and transformed indolent B cell lymphoma.
Stage Note: Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL and CLL; all others are early stage.
PCD - Multiple myeloma
Disease Stage: Advanced StageDRI Assignment: High2-year Overall Survival*: 33% (31-35)*95% confidence intervals
- PCD - Multiple myeloma
- Advanced Stage
- High
- 33% (31-35)
PCD - Multiple myeloma
Disease Stage: Complete remission/very good partial remission/partial remissionDRI Assignment: Intermediate2-year Overall Survival*: 51% (50-52)*95% confidence intervals
- PCD - Multiple myeloma
- Complete remission/very good partial remission/partial remission
- Intermediate
- 51% (50-52)